Hepion pharmaceuticals receives fda orphan drug status designation for rencofilstat for the treatment of hepatocellular carcinoma

Edison, n.j., june 20, 2022 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical mid-stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”) and hepatocellular carcinoma (“hcc”), today announced that the u.s. food and drug administration (“fda”) has granted orphan drug designation to rencofilstat, a liver-targeting, orally administered, novel cyclophilin inhibitor, for the treatment of hcc.
HEPA Ratings Summary
HEPA Quant Ranking